DE2217817C2 - Pharmazeutisches Präparat zur Behandlung von oder zum Schutz gegen autoimmune Erkrankungen, die das Gehirn angreifen - Google Patents

Pharmazeutisches Präparat zur Behandlung von oder zum Schutz gegen autoimmune Erkrankungen, die das Gehirn angreifen

Info

Publication number
DE2217817C2
DE2217817C2 DE2217817A DE2217817A DE2217817C2 DE 2217817 C2 DE2217817 C2 DE 2217817C2 DE 2217817 A DE2217817 A DE 2217817A DE 2217817 A DE2217817 A DE 2217817A DE 2217817 C2 DE2217817 C2 DE 2217817C2
Authority
DE
Germany
Prior art keywords
pharmaceutical preparation
brain
amino acid
lysine
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2217817A
Other languages
German (de)
English (en)
Other versions
DE2217817A1 (ref
Inventor
Ruth Prof. Arnon
Tvsi Dr. Hirshfeld
Asher Dr. Meshorer
Michael Prof. Rehovot Sela
Dvora Ramat Gan Teitelbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of DE2217817A1 publication Critical patent/DE2217817A1/de
Application granted granted Critical
Publication of DE2217817C2 publication Critical patent/DE2217817C2/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Polyamides (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE2217817A 1971-04-21 1972-04-13 Pharmazeutisches Präparat zur Behandlung von oder zum Schutz gegen autoimmune Erkrankungen, die das Gehirn angreifen Expired DE2217817C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL36670A IL36670A (en) 1971-04-21 1971-04-21 Therapeutic basic copolymers of amino acids

Publications (2)

Publication Number Publication Date
DE2217817A1 DE2217817A1 (ref) 1972-11-16
DE2217817C2 true DE2217817C2 (de) 1983-05-05

Family

ID=11045887

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2217817A Expired DE2217817C2 (de) 1971-04-21 1972-04-13 Pharmazeutisches Präparat zur Behandlung von oder zum Schutz gegen autoimmune Erkrankungen, die das Gehirn angreifen

Country Status (8)

Country Link
US (1) US3849550A (ref)
JP (1) JPS5710132B1 (ref)
CA (1) CA1006508A (ref)
CH (1) CH570167A5 (ref)
DE (1) DE2217817C2 (ref)
FR (1) FR2133926B1 (ref)
GB (1) GB1393435A (ref)
IL (1) IL36670A (ref)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466445A (en) * 1985-06-18 1995-11-14 Emory University Methods for reducing salmonella in chickens
US5494660A (en) * 1985-06-18 1996-02-27 Emory University Method for inhibiting microbial binding to surfaces
USRE35862E (en) * 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) * 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5443841A (en) * 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5401516A (en) * 1992-12-21 1995-03-28 Emisphere Technologies, Inc. Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ATE204467T1 (de) * 1993-04-22 2001-09-15 Emisphere Tech Inc Orale darreichungsform
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
RU2198900C2 (ru) * 1994-05-24 2003-02-20 Еда Рисерч энд Дивелопмент Ко., Лтд. Усовершенствованный сополимер-1 и способ его получения
AU741590B2 (en) * 1994-05-24 2001-12-06 Yeda Research And Development Co. Ltd. Copolymer-1 improvements in compositions of copolymers
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
AU775214B2 (en) * 1994-05-24 2004-07-22 Yeda Research And Development Co. Ltd. Copolymer-1 improvements in compositions of copolymers
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US5820881A (en) * 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US6051258A (en) * 1995-06-07 2000-04-18 Emisphere Technologies, Inc. Proteinoid emulsions and methods for preparation and use thereof
US5824345A (en) * 1995-06-07 1998-10-20 Emisphere Technologies, Inc. Fragrances and flavorants
US5667806A (en) * 1995-06-07 1997-09-16 Emisphere Technologies, Inc. Spray drying method and apparatus
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
WO1997010197A1 (en) * 1995-09-11 1997-03-20 Emisphere Technologies, Inc. METHOD FOR PREPARING φ-AMINOALKANOIC ACID DERIVATIVES FROM CYCLOALKANONES
IL116559A (en) 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
CA2258264A1 (en) 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US5879681A (en) * 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5939381A (en) * 1997-02-07 1999-08-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) * 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5876710A (en) * 1997-02-07 1999-03-02 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) * 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6531130B1 (en) 1999-07-06 2003-03-11 The Board Of Trustees Of The Leland Stanford University Treatment of demyelinating autoimmune disease with ordered peptides
PT1248643E (pt) * 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
DK1294390T3 (da) * 2000-06-07 2006-04-03 Yeda Res & Dev Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
IL148202A0 (en) * 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
IL137460A0 (en) 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
SI1459065T1 (sl) * 2001-12-04 2010-11-30 Teva Pharma Postopki za merjenje potentnosti glatiramer acetata
IL160105A0 (en) * 2001-12-06 2004-06-20 Yeda Res & Dev Vaccine for treatment of motor neurone diseases
WO2004043995A2 (en) * 2002-11-13 2004-05-27 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
CA2411786C (en) 2002-11-13 2009-01-27 Brantford Chemicals Inc. A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
EP1603530A1 (en) * 2003-03-04 2005-12-14 Teva Pharmaceutical Industries Limited Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
CA2520865A1 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US20050170004A1 (en) * 2003-10-31 2005-08-04 Vered Rosenberger Nanoparticles for drug delivery
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
KR20060125916A (ko) * 2004-03-01 2006-12-06 펩팀문, 인코포레이티드 자가면역 질병을 치료하기 위한 방법 및 조성물
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
KR20070036062A (ko) 2004-05-07 2007-04-02 펩팀문, 인코포레이티드 랜덤 공중합체에 의해 질병을 치료하는 방법
WO2005112911A2 (en) * 2004-05-21 2005-12-01 The Regents Of The University Of California Compositions and methods for treating myelin deficiency disorders
CA2571035A1 (en) 2004-06-25 2006-01-12 Id Biomedical Corporation Of Quebec Compositions and methods for treating neurological disorders
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US7495072B2 (en) * 2004-09-09 2009-02-24 Teva Pharmaceutical Industries, Ltd. Process for preparation of mixtures of polypeptides using purified hydrobromic acid
AU2005302500B2 (en) * 2004-10-29 2008-11-27 Sandoz Ag Processes for preparing glatiramer
KR20070108388A (ko) * 2005-02-02 2007-11-09 테바 파마슈티컬 인더스트리즈 리미티드 가수소분해를 이용한 폴리펩타이드의 혼합물의 제조방법
US20070141663A1 (en) * 2005-08-15 2007-06-21 Jinguo Ding Process for the preparation of copolymer-1
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
WO2007127977A2 (en) 2006-04-28 2007-11-08 Momenta Pharmaceuticals, Inc. Methods of evaluating peptide mixtures
KR100831796B1 (ko) * 2006-05-29 2008-05-28 엘지전자 주식회사 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
CA2656463C (en) 2006-06-28 2015-12-01 Yeda Research And Development Co. Ltd. Method of treatment of age-related macular degeneration
EP2134176A4 (en) * 2007-03-30 2012-08-29 Brigham & Womens Hospital COMPOUNDS AND METHODS FOR ENHANCING MHC CLASS II THERAPIES
WO2008157697A2 (en) * 2007-06-21 2008-12-24 Momenta Pharmaceuticals, Inc. Copolymer assay
US8993722B2 (en) * 2007-07-31 2015-03-31 Natco Pharma Limited Process for the preparation glatiramer acetate (copolymer-1)
WO2009017775A2 (en) * 2007-08-02 2009-02-05 Scinopharm Taiwan Ltd. Process for the preparation of a polypeptide
US8193147B2 (en) 2007-09-24 2012-06-05 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
ES2449865T5 (es) 2008-04-16 2022-11-18 Momenta Pharmaceuticals Inc Análisis de composiciones de copolímeros de aminoácidos
JP2011530523A (ja) * 2008-08-07 2011-12-22 サイノファーム タイワン リミテッド 酢酸グラチラマーの合成
US9617313B2 (en) 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
RU2402576C1 (ru) * 2009-02-20 2010-10-27 Закрытое Акционерное Общество "Фарм-Синтез" Пептидный сополимер, способ его получения и фармацевтическая композиция на его основе
EP2414384B2 (en) 2009-04-03 2023-05-03 Momenta Pharmaceuticals, Inc. Control of copolymer compositions
US9150609B2 (en) 2009-06-04 2015-10-06 Council Of Scientific & Industrial Research Process for the preparation of copolymer-1 using a polymer supported dialkylamine initiator
US8691790B2 (en) * 2009-07-27 2014-04-08 James Layne Boucher Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
ES2612001T4 (es) 2009-08-20 2018-02-07 Yeda Research & Development Company, Ltd. Terapia de baja frecuencia con acetato de glatirámero
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
JP5916622B2 (ja) 2010-01-04 2016-05-11 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
WO2011086470A1 (en) 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
WO2012054518A1 (en) * 2010-10-18 2012-04-26 Lanco Biosciences, Inc. Delivery of copolymers by microinjection systems
CA2827275A1 (en) 2011-02-14 2012-09-20 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
WO2012150495A1 (en) 2011-05-05 2012-11-08 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
EP2642290A1 (en) 2012-03-19 2013-09-25 Synthon BV Glatiramer acetate human monocytic cell line-based potency assay
WO2013139728A1 (en) 2012-03-19 2013-09-26 Synthon Bv Glatiramer acetate human monocyte cell-based potency assay
MX2015004563A (es) 2012-10-10 2015-07-14 Teva Pharma Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
WO2014060942A2 (en) * 2012-10-20 2014-04-24 Mahesh Kandula Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
DK2774640T3 (en) 2013-03-08 2015-02-02 Teva Pharma Reusable injection device for a syringe
PL2774639T3 (pl) 2013-03-08 2015-07-31 Teva Pharma Wielorazowe urządzenie strzykawkowe dla strzykawki
WO2014159685A2 (en) 2013-03-14 2014-10-02 Mylan Inc. Glatiramer acetate response biomarker mrna potency assay
WO2014173463A1 (en) 2013-04-26 2014-10-30 Synthon Bv Glatiramer acetate human monocytic cell line-based potency assay
CN103265624B (zh) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 格拉替雷的制备方法
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9995734B2 (en) 2013-10-24 2018-06-12 Mylan Inc. Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
WO2015101988A1 (en) 2013-12-31 2015-07-09 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
AU2015228372B2 (en) 2014-03-12 2018-05-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
WO2016029920A1 (en) 2014-08-29 2016-03-03 Aarhus Universitet Positively charged co-polymers for use as antimicrobial agents
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
EP3147667B1 (en) 2015-09-24 2019-06-12 CHEMI S.p.A. Analysis of the molecular weight distribution of complex polypeptide mixtures
ES2707500T3 (es) 2015-11-23 2019-04-03 Chemi Spa Análisis mediante RP-HPLC de mezclas de polipéptidos complejos
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu) 2016-08-31 2025-07-28 Mapi Pharma Ltd Glatiramer-acetátot tartalmazó depórendszerek
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
AU2018270396B2 (en) 2017-05-15 2025-03-20 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
WO2018211486A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
WO2019175869A1 (en) 2018-03-12 2019-09-19 Yeda Research And Development Co. Ltd Treatment of a heart disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB822192A (en) * 1956-08-29 1959-10-21 Ilford Ltd Improvements in or relating to the production of photographic emulsions

Also Published As

Publication number Publication date
JPS5710132B1 (ref) 1982-02-25
GB1393435A (en) 1975-05-07
IL36670A (en) 1974-09-10
CA1006508A (en) 1977-03-08
US3849550A (en) 1974-11-19
DE2217817A1 (ref) 1972-11-16
FR2133926A1 (ref) 1972-12-01
FR2133926B1 (ref) 1975-12-26
CH570167A5 (ref) 1975-12-15
IL36670A0 (en) 1971-06-23

Similar Documents

Publication Publication Date Title
DE2217817C2 (de) Pharmazeutisches Präparat zur Behandlung von oder zum Schutz gegen autoimmune Erkrankungen, die das Gehirn angreifen
DE69429169T2 (de) Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält
DE69230789T2 (de) Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
DE69127470T2 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
DE69734653T2 (de) Pharmazeutische formulierung, bestehend aus menschlichem wachstumshormon, histidine und einem nichtionischen detergenz
DE2606118C2 (de) Verfahren zur Herstellung eines gereinigten Gamaglobulins und intravenös verabreichbares Arzneimittel
DE3689909T2 (de) Verwendung eines GHL-Cu enthaltenden Stoffes zur Herstellung eines Arzneimittels für Wunden.
DE69525340T2 (de) Verbesserungen in zusammensetzungen von kopolymeren enthaltend kopolymer-1
EP0585552B1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE69827357T2 (de) Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
DE2415101A1 (de) Pharmazeutische zusammensetzungen
DE3827533A1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus
EP0430200A1 (de) Arzneimittel zur subkutanen oder intramuskulären Applikation enthaltend Polypeptide
EP0065747A1 (de) Nonapeptid zur Behandlung von Suchtmittelentzugserscheinungen
DE726075T1 (de) Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
DE69631930T2 (de) Stabilisiertes wässriges flüssiges Blutgerinnungsfaktor XIII-Präparat
DE3418820C2 (ref)
CH650678A5 (de) Pharmazeutisches mittel aus human-insulin und human-proinsulin.
DE69525349T2 (de) Behandlung von sclaganfall mit einer infiltration von makrophagen assoziiert
DE60128399T2 (de) Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen
DE60028559T2 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
DE4413938A1 (de) Peptide als Therapeutikum für Autoimmunerkrankungen
EP0493662A1 (de) Verwendung von Superoxiddismutasen für die Herstellung von Arzneimitteln zur Prophylaxe und/oder Behandlung von Organversagen bei Risikopatienten mit Polytrauma als Unfallfolge
DE3239710C2 (de) Peptid mit Nerven-regenerierenden Eigenschaften
Foley Immunity of C3H mice to lymphosarcoma 6-C3H-Ed following regression of the implanted tumor

Legal Events

Date Code Title Description
OD Request for examination
8126 Change of the secondary classification

Free format text: C08L 77/04 A61K 31/00 A61K 37/00

8180 Miscellaneous part 1

Free format text: DIE BEZEICHNUNG LAUTET RICHTIG: PHARMAZEUTISCHES PRAEPARAT ZUR BEHANDLUNG VON ODER ZUM SCHUTZ GEGENAUTOIMMUNE ERKRANKUNGEN, DIE DAS GEHIRN ANGREIFEN

8181 Inventor (new situation)

Free format text: TEITELBAUM, DVORA, RAMAT GAN, IL MESHORER, ASHER, DR. HIRSFELD, TVSI, DR. ARNON, RUTH, PROF. SELA, MICHAEL, PROF., REHOVOT, IL

D2 Grant after examination
8364 No opposition during term of opposition